文献速递免疫规划

一项III期、多中心、随机、双盲、阳性对照研究:评估15价肺炎球菌结合疫苗V114补种方案在健康婴幼儿、儿童和青少年中的安全性、耐受性和免疫原性(PNEU-PLAN)

A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN).
PubMed 文献 · Vaccine · 2022-09-21

这项III期描述性研究将606名7月龄至17岁健康儿童随机分配接种V114或PCV13,按年龄组采用补种方案。V114总体耐受良好,对全部15种血清型具免疫原性,包括PCV13未含的22F和33F。结果支持对PCV免疫不完整或无免疫儿童进行V114补种。

要点

  • V114补种在7月龄至17岁健康儿童中总体耐受良好。
  • 接种后30天,13种共享血清型IgG几何平均浓度两组相当。
  • V114组22F和33F血清型IgG几何平均浓度高于PCV13组。

核心结论

  • V114补种在7月龄至17岁健康个体中总体耐受良好,对全部15种血清型具免疫原性,包括PCV13未含的血清型,无论既往是否接种过肺炎球菌疫苗。
  • 结果支持对PCV免疫不完整或无免疫的儿童按推荐程序进行V114补种。

研究设计与样本

  • III期、多中心、随机、双盲、阳性对照、描述性研究(NCT03885934)。
  • 共606名7月龄至17岁健康儿童随机接种V114(n=303)或PCV13(n=303),按三个年龄组(7-11月龄、12-23月龄、2-17岁)采用年龄相应的补种方案。
  • 研究对象为肺炎球菌疫苗未接种或既往接种过低价肺炎球菌结合疫苗的健康儿童。

主要发现

  • 7-11月龄和2-17岁年龄组中,V114组和PCV13组报告不良事件(AEs)的儿童比例相似。
  • 12-23月龄组报告AEs的儿童比例V114组为79.0%,PCV13组为59.4%,V114组数值上更高。
  • 各年龄组报告严重不良事件(SAEs)的儿童比例不同,但接种组间总体相当。
  • 未报告疫苗相关严重不良事件,无死亡发生。
  • 末剂PCV后30天,13种共享血清型的血清型特异性免疫球蛋白G几何平均浓度两组相当,V114组22F和33F的几何平均浓度更高。

临床怎么用

  • 作者认为,结果支持对PCV免疫不完整或无免疫的儿童按推荐程序进行V114补种。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite widespread use of pneumococcal conjugate vaccines (PCVs) in children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In addition, many children do not complete their PCV course on schedule. V114 is a 15-valent PCV that contains two epidemiologically important serotypes, 22F and 33F, in addition to the 13 serotypes present in PCV13, the licensed 13-valent PCV. METHODS: This phase III descriptive study evaluated safety and immunogenicity of catch-up vaccination with V114 or PCV13 in healthy children 7 months-17 years of age who were either pneumococcal vaccine-naïve or previously immunized with lower valency PCVs (NCT03885934). Overall, 606 healthy children were randomized to receive V114 (n = 303) or PCV13 (n = 303) via age-appropriate catch-up vaccination schedules in three age cohorts (7-11 months, 12-23 months, or 2-17 years). RESULTS: Similar proportions of children 7-11 months and 2-17 years of age reported adverse events (AEs) in the V114 and PCV13 groups. A numerically greater proportion of children 12-23 months of age reported AEs in the V114 group (79.0%) than the PCV13 group (59.4%). The proportions of children who reported serious AEs varied between different age cohorts but were generally comparable between vaccination groups. No vaccine-related serious AEs were reported, and no deaths occurred. At 30 days after the last PCV dose, serotype-specific immunoglobulin G geometric mean concentrations were comparable between vaccination groups for the 13 shared serotypes and higher in the V114 group for 22F and 33F. CONCLUSIONS: Catch-up vaccination with V114 in healthy individuals 7 months-17 years of age was generally well tolerated and immunogenic for all 15 serotypes, including those not contained in PCV13, regardless of prior pneumococcal vaccination. These results support V114 catch-up vaccination in children with incomplete or no PCV immunization per the recommended schedule.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Banniettis N, Wysocki J, Szenborn L, et al. A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN). Vaccine. 2022. PMID: 36150974. doi:10.1016/j.vaccine.2022.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。